With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Sustainable Fertiliser Production Process wins RSC Prize
without a concerted effort from a diverse and harmonious team of highly talented scientists motivated by achieving one globally important goal.”
Monash Ammonia Team (credit: RSC Monash University)
Helen Pain (Credit:RSC)
The Royal Society of Chemistry (RSC) has named a team from Australia’s Monash University as recipients of its prestigious Environment, Sustainability and Energy Horizon Prize: John Jeyes Prize, for their ground-breaking discovery of a more sustainable approach to production of ammonia-based fertilizers.
The Monash Ammonia team has developed a unique electrolyte [1] that supports the reaction to convert nitrogen into ammonia at near ambient pressures, using just renewable energy, nitrogen from the air and room temperature water. The group has also formed spin-out company, Jupiter Ionics, to scale up the process.
Receiving a trophy and a professionally produced video to celebrate the work, Associate Professor Alexandr N. Simonov, ARC Future Fellow, School of Chemistry, of Monash University and the Monash Ammonia team, said: “The success of our work would never be possible
The Monash Ammonia team’s work has tackled the geo-political events impacting food production and high dependence on nitrogenous fertilisers, by facilitating a decentralised approach to fertiliser production, capable of using renewable energy at times when it is available in abundance and otherwise may be wasted. The approach is working towards a shift in the way food is produced through not only not only decarbonising processes, but also democratising them.
Dr Helen Pain, Chief Executive of the Royal Society of Chemistry, said: “The Horizon Prizes recognise brilliant teams and collaborations who are opening new directions and possibilities in their fi eld, by combining their diversity of thought, experience and skills, to deliver scientifi c developments for the benefi t of all of us.
“The work of the Monash Ammonia team is a fantastic example of why we celebrate great science; not only because of how they have expanded our understanding of the world around us, but also because of the incredible contribution they make to society as a whole. We are very proud to recognise their work.”
1. Published in Nature volume 609, pages722–727 (2022) More information online:
ilmt.co/PL/Re9G
60566pr@reply-direct.com
Success of MSC Development Target Triggers Milestone Payment
Alastair Smith
Life sciences company Avacta has announced a second milestone equity payment increasing its shareholding in AffyXell Therapeutics, a joint venture to develop next- generation cell therapies between Avacta and Daewoong Pharmaceutical in South Korea.
Indian Production Facility to help ease Capacity and Quality Issues
chain. The introduction of Velocity® Vials will contribute to the ongoing evolution of our offerings and services and will expand our portfolio of high-quality tubular glass packaging,” said Olivier Rousseau, CEO SGD Pharma. “We see an opportunity for the industry to improve drug fi lling quality and performance capabilities by transitioning to Corning’s coated vial technology.”
Pictured forefront: Olivier Rousseau and Ron Verkleeren conduct ground breaking ceremony in Vemula
A new joint venture that includes the opening of a pharmaceutical glass tubing facility in India; offerings of enhanced vial quality; improved fi lling-line productivity; and faster worldwide delivery of injectable treatments, has been announced by glass-coatings specialist Corning Inc and SGD Pharma, a global producer of molded and tubular glass for the pharmaceutical primary packaging industry.
Olivier Rousseau, CEO SGD Pharma and Ron Verkleeren, Senior Vice President and General Manager of Corning’s Life Sciences Market Access Platform, were amongst guests at the ground-breaking celebrations for the new production facility based in Vemula, Telangana.
“The partnership with Corning represents yet another step in our strategy to advance converting technology in the pharmaceutical industry and secure our supply
SGD Pharma joins a growing network of leading primary- packaging manufacturers adopting Corning’s coating technology. The joint venture expands Velocity Vials’ manufacturing footprint, localises its supply chains in India, and enables easier adoption of the technology by customers.
Corning is advancing pharmaceutical glass technology to help our customers address their most pressing challenges – globally and locally,” said Ron Verkleeren, Senior Vice President and General Manager of Corning’s Life Sciences Market Access Platform. “The joint venture with SGD Pharma supports our continued global expansion as we localise manufacturing for our customers. The collaboration also strengthens our leadership position in the industry and underscores our commitment to India’s high-growth market.”
Manufacturing of Velocity Vials at SGD Pharma’s facility in Vemula, India, is expected to begin in 2024. Pharmaceutical tubing production is expected to begin in 2025.
More information online:
ilmt.co/PL/qjp1 60592pr@reply-direct.com
Following successful development and characterisation of Affi mer® proteins against the second target of interest for AffyXell, application to fi le a patent for the associated intellectual property triggered the second milestone. The exact increase in the shareholding will be determined, as with the fi rst milestone payment, following a formal valuation of the joint company.
Established in January 2020, AffyXell develops novel mesenchymal stem cell (MSC) therapies.
Dr Alastair Smith, Chief Executive Offi cer of Avacta Group, said: “We are delighted that such rapid progress has been made with the second target in our joint venture in South Korea. There is great potential for AffyXell’s novel, engineered mesenchymal stem cell platform incorporating Avacta’s Affi mer® technology to deliver signifi cant improvements to the standard of care for patients with serious diseases.
“We continue to work closely with our colleagues at AffyXell and Daewoong to advance this cutting edge therapeutic platform.”
More information online:
ilmt.co/PL/OpWp 60593pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
